The deputy governor described Canada as caught in a "vicious circle" where weak business investment leads to lower productivity, which results in slower wage growth. This in turn reduces household ...

In a separate announcement, Warner Music also revealed a collaboration with Stability AI to develop professional-grade tools for artists, songwriters, and producers using ethically trained models.

S&P Global Ratings expects the deal to boost Akzo’s profitability over time, with adjusted EBITDA margins potentially rising to 19%-20% during the next two years. The companies have identified $600 ...

Investing.com -- S&P Global Ratings has revised its outlook on Cineplex Inc. to negative from stable while affirming its ’B+’ rating, citing elevated leverage and a weak film slate.

Investing.com -- President Donald Trump suggested he would fire Treasury Secretary Scott Bessent if he doesn’t help secure ...

For 2026 specifically, Block forecasts 17% YoY gross profit growth to $11.98 billion, with adjusted operating income and adjusted earnings per share growing over 30% to $2.70 billion and $3.20 ...

Investing.com -- OpenAI has introduced ChatGPT for Teachers, a free AI workspace designed specifically for educators, available at no cost to verified U.S. K-12 teachers through June 2027.

Today will be all about Nvidia’s (NVDA) quarterly announcement and the grand finale of this earnings announcement season. As always, Nvidia’s guidance will be crucial. Click here to listen to Louie’s ...

According to Fitch, the downgrade reflects Braskem Idesa’s entry into a grace period following non-payment of a material financial obligation. The company missed an interest payment due on Tuesday and ...

Investing.com -- Eversource Energy (NYSE:ES) stock fell 11% after Connecticut regulators denied the utility company’s request ...

Match Group emerges as the clear sector leader, with compelling valuation metrics and strategic initiatives that could drive share price appreciation. Meanwhile, lesser-known competitors offer ...

Investing.com -- Fulcrum Therapeutics (NASDAQ:FULC) stock surged 20% after competitor Agios Pharmaceuticals reported mixed results from its sickle cell disease (SCD) drug trial, potentially clearing a ...